循環器ジャーナル66巻3号

2018年07月発行

特集 肺高血圧症Cutting Edge Ⅳ．肺高血圧症治療：内科的治療と外科的治療，そして将来の治療

エンドセリン受容体拮抗薬—受容体選択性は考慮すべきか？　何を根拠に選択するのか？

著者： 玉田直己¹ 江本憲昭¹²

所属機関： ¹神戸大学大学院医学研究科内科学講座循環器内科学分野 ²神戸薬科大学臨床薬学研究室

ページ範囲：P.404 - P.410

Point
・エンドセリン系は肺動脈の収縮や血管平滑筋細胞の増殖など，肺動脈性肺高血圧症の病態形成に関わっている．
・エンドセリン受容体拮抗薬は肺動脈性肺高血圧症治療のキープレーヤーとなる薬剤である．
・エンドセリンが作用する細胞内情報伝達経路には未だ不明な点も多く残されており今後の研究課題である．

参考文献

1) Yanagisawa M, Kurihara H, Kimura S, et al:A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411-415, 1988

2) Miyagawa K, Emoto N:Current state of endothelin receptor antagonism in hypertension and pulmonary hypertension. Ther Adv Cardiovasc Dis 8:202-216, 2014

3) Vignon-Zellweger N, Heiden S, Miyauchi T, et al:Endothelin and endothelin receptors in the renal and cardiovascular systems. Life Sci 91:490-500, 2012

4) Opitz CF, Ewert R, Kirch W, et al:Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension:does selectivity matter? Eur Heart J 29:1936-1948, 2008

5) Davenport AP, Hyndman KA, Dhaun N, et al:Endothelin. Pharmacol Rev 68:357-418, 2016

6) Channick RN, Simonneau G, Sitbon O, et al:Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension:a randomised placebo-controlled study. Lancet（London, England）358:1119-1123, 2001

7) Rubin LJ, Badesch DB, Barst RJ, et al:Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896-903, 2002

8) Galie N, Beghetti M, Gatzoulis MA, et al:Bosentan therapy in patients with Eisenmenger syndrome:a multicenter, double-blind, randomized, placebo-controlled study. Circulation 114:48-54, 2006

9) Galie N, Rubin L, Hoeper M, et al:Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan（EARLY study）:a double-blind, randomised controlled trial. Lancet（London, England）371:2093-2100, 2008

10) Korn JH, Mayes M, Matucci Cerinic M, et al:Digital ulcers in systemic sclerosis:prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50:3985-3993, 2004

11) Khanna D, Denton CP, Merkel PA, et al:Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis:DUAL-1 and DUAL-2 Randomized Clinical Trials. JAMA 315:1975-1988, 2016

12) Barst RJ, Langleben D, Frost A, et al:Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 169:441-447, 2004

13) Galie N, Olschewski H, Oudiz RJ, et al:Ambrisentan for the treatment of pulmonary arterial hypertension:results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy（ARIES）study 1 and 2. Circulation 117:3010-3019, 2008

14) Galie N, Barbera JA, Frost AE, et al:Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med 373:834-844, 2015

15) Pulido T, Adzerikho I, Channick RN, et al:Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 369:809-818, 2013

16) Rosano L, Bagnato A:beta-arrestin1 at the cross-road of endothelin-1 signaling in cancer. J Exp Clin Cancer Res 35:121, 2016

17) Shihoya W, Nishizawa T, Okuta A, et al:Activation mechanism of endothelin ETB receptor by endothelin-1. Nature 537:363-368, 2016

18) Shihoya W, Nishizawa T, Yamashita K, et al:X-ray structures of endothelin ETB receptor bound to clinical antagonist bosentan and its analog. Nat Struct Mol Biol 24:758-764, 2017